Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 193264 | PF-06835919 ( MDK-1846 ) | 2102501-84-6 | ≧98.0% | _2102501-84-6.png) |
| MDK1846 is a potent ketohexokinase (KHK) inhibitor. | ||||
| 171454 | 1-(4-Bromo-6- methylpyridin-2- yl)ethan-1-one | 1060810-24-3 | ≧98.0% | ethan-1-one_1060810-24-3.png) |
| 1-(4-Bromo-6- methylpyridin-2- yl)ethan-1-one, CAS 1060810-24-3. | ||||
| 25176 | AG-270 | 2201056-66-6 | ≧98.0% |  |
| MAT2A Inhibitor AG-270 is an orally available small molecule inhibitor of methionine | ||||
| 184163 | 2-amino-3-methoxy-4-(3-morpholin-4-ylpropoxy)benzonitrile | 1032570-98-1 | >96% |  |
| 2-amino-3-methoxy-4-(3-morpholin-4-ylpropoxy)benzonitrile is a drug intermediate. | ||||
| 20657 | Zilurgisertib | 2173389-57-4 | ≧98.0% |  |
| Zilurgisertib (earlier known as INCB 00928) is an activin receptor-like kinase-2 (ALK | ||||
| 25177 | Dencatistat | 2377000-84-3 | ≧98.0% |  |
| Dencatistat is an orally bioavailable, small molecule inhibitor of cytidine triphosph | ||||
| 20266 | Linzagolix | 935283-04-8 | ≧98.0% |  |
| Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially | ||||
| 20636 | Edecesertib ( GS-5718 ) | 2408839-73-4 | ≧98.0% | _2408839-73-4.png) |
| GS-5718 (Edecesertib) is a potent, selective, orally bioavailable IRAK4 inhibitor. | ||||
| 24107 | LXH-3-71 | 2251753-65-6 | ≧97.0% |  |
| LXH-3-71 isnovel "molecular glue"that induces the interaction between PHGDH | ||||
| 51802 | TIC10 ( ONC201 ) | 1616632-77-9 | 99.85% |  |
| TIC10 ( ONC201 ), Bulk in stock, contact us by email for detailed quotation.ONC201/TI | ||||
| 20509 | Cadefrecitinib (GLPG-3667) | 2308520-97-8 | ≧98.0% |  |
| Cadefrecitinib (GLPG-3667) is an oral, small molecule inhibitor of the TYK2 kinase in | ||||
| 20625 | Orismilast ( LEO-32731 ) | 1353546-86-7 | ≧98.0% |  |
| Orismilast is a phosphodiesterase type 4 (PDE4) inhibitor. | ||||